STAAR Surgical Company (STAA)

Currency in USD
24.09
-2.09(-7.98%)
Closed·
24.10+0.01(+0.04%)
·
STAA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.8225.96
52 wk Range
15.5935.87
Key Statistics
Prev. Close
26.18
Open
25.96
Day's Range
23.82-25.96
52 wk Range
15.59-35.87
Volume
1.53M
Average Volume (3m)
882.8K
1-Year Change
-15.0864%
Book Value / Share
7.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
STAA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.20
Upside
+17.06%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

STAAR Surgical Company News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
8 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 28.20
(+17.06% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Hold28.00+16.23%31.00MaintainAug 17, 2026
Jefferies
Hold28.00+16.23%29.00MaintainAug 13, 2026
Piper Sandler
Hold33.00+36.99%-MaintainAug 13, 2026
UBS
Sell19.00-21.13%20.00MaintainAug 13, 2026
UBS
Sell20.00-16.98%-New CoverageJul 28, 2026

STAAR Surgical Company Earnings Call Summary for Q2/2026

  • Q2 revenue surged 111% YoY to $93.5M, beating estimates, but EPS of $0.16 missed consensus $0.22 forecast by 27%, pressuring shares after-hours.
  • China sales jumped 100%+ YoY to $52.3M, driving growth; EVO+ demand exceeded supply, now comprising one-third of China unit volume at premium pricing.
  • Company returned to profitability with $8.1M net income vs. $16.8M loss last year; gross margin improved to 74.5%, ended quarter with $181.5M cash, zero debt.
  • Management expects Q3 China revenue to decline sequentially due to seasonality; EVO+ supply constraints should ease by Q3-end, full-year 2026 revenue growth forecast at 39%.
  • CEO Foust announced plans to diversify beyond single-product model, hiring chief technology officer; targeting 100% Swiss manufacturing for China shipments by year-end to mitigate tariffs.
Last Updated: 2026-08-12, 06:32 p/m
Read Full Transcript

Earnings

Latest Release
Aug 12, 2026
EPS / Forecast
0.16 / 0.14
Revenue / Forecast
93.5M / 90.17M
EPS Revisions
Last 90 days

STAA Income Statement

Compare STAA to Peers and Sector

Metrics to compare
STAA
Peers
Sector
Relationship
P/E Ratio
314.7x7.3x−0.4x
PEG Ratio
3.29−0.180.00
Price/Book
3.3x2.3x2.6x
Price / LTM Sales
3.6x2.4x3.1x
Upside (Analyst Target)
5.0%17.6%47.9%
Fair Value Upside
Unlock15.7%6.3%Unlock

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
14.32M28.76%374.91M
Other Institutional Investors
63.63M71.24%1.67B
Public Companies & Retail Investors
0.000.00%0.00
Total
77.95M100.00%2.04B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Broadwood Partners LP32.38%16,123,842422,122
Broadwood Capital, Inc.32.38%16,123,842422,122

People Also Watch

36.26
GLOB
-3.00%
60.64
FTV
-1.59%
188.27
EXPD
+1.16%

FAQ

What Is the STAAR Surgical (STAA) Stock Price Today?

The STAAR Surgical stock price today is 24.09 USD.

What Stock Exchange Does STAAR Surgical Trade On?

STAAR Surgical is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for STAAR Surgical?

The stock symbol for STAAR Surgical is "STAA."

What Is the STAAR Surgical Market Cap?

As of today, STAAR Surgical market cap is 1.31B USD.

What Is STAAR Surgical's Earnings Per Share (TTM)?

The STAAR Surgical EPS (TTM) is 0.08.

When Is the Next STAAR Surgical Earnings Date?

STAAR Surgical will release its next earnings report on Nov 04, 2026.

From a Technical Analysis Perspective, Is STAA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has STAAR Surgical Stock Split?

STAAR Surgical has split 1 times.

How Many Employees Does STAAR Surgical Have?

STAAR Surgical has 921 employees.

What is the current trading status of STAAR Surgical (STAA)?

As of Aug 17, 2026, STAAR Surgical (STAA) is trading at a price of 24.09 USD, with a previous close of 26.18 USD. The stock has fluctuated within a day range of 23.82 USD to 25.96 USD, while its 52-week range spans from 15.59 USD to 35.87 USD.

What Is STAAR Surgical (STAA) Price Target According to Analysts?

The average 12-month price target for STAAR Surgical is 28.20 USD, with a high estimate of 37 USD and a low estimate of 19 USD. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +17.06% Upside potential.

What Is the STAA Premarket Price?

STAA's last pre-market stock price is 26.17 USD. The pre-market share volume is 300.00, and the stock has decreased by -0.01, or -0.04%.

What Is the STAA After Hours Price?

STAA's last after hours stock price is 24.10 USD, the stock has decreased by 0.01, or 0.04%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.